文献速递乳腺乳腺X线

联合癌症征象、遮蔽与风险的人工智能评分用于筛选补充性乳腺癌筛查患者

Use of an AI Score Combining Cancer Signs, Masking, and Risk to Select Patients for Supplemental Breast Cancer Screening.
PubMed 文献 · Radiology · 2024-01-01

该回顾性研究纳入2008年1月至2015年12月在Karolinska大学医院接受筛查性乳腺X线摄影的65 325次检查,评估整合癌症征象、遮蔽和风险的AISmartDensity评分在筛查阴性后识别未来乳腺癌的能力。AISmartDensity的AUC为0.72,优于最佳密度模型(年龄校正致密面积)的0.61(P < .001);在评分前8%的检查中,AISmartDensity识别出455例未来癌症中的152例(33%),PPV为2.91%,而最佳密度模型识别出57例(13%),PPV为1.09%(P < .001)。

要点

  • AISmartDensity在筛查阴性后识别未来乳腺癌的AUC为0.72,优于最佳密度模型的0.61(P < .001)。
  • 评分前8%时,AISmartDensity识别33%(152/455)的未来癌症,PPV为2.91%;最佳密度模型识别13%(57/455),PPV为1.09%。
  • AISmartDensity识别32%(41/130)的间期癌和34%(111/325)的下一轮筛查检出癌,最佳密度模型分别识别16%(21/130)和9%(30/325)。

核心结论

  • 整合癌症征象、遮蔽和风险的AISmartDensity评分在筛查性乳腺X线摄影阴性后识别需补充成像的患者方面优于传统乳腺密度模型。

研究设计与样本

  • 回顾性研究,纳入2008年1月至2015年12月在Karolinska大学医院随机选取的接受筛查性乳腺X线摄影者,共65 325次检查(患者中位年龄53岁,IQR 47-62岁),其中健康者64 870次检查、筛查阴性后3年内诊断乳腺癌者455次检查;AISmartDensity各模型使用非重叠数据训练和验证,并与乳腺密度模型比较。

诊断标准与关键数值

  • AISmartDensity检测后续癌症的AUC为0.72,最佳密度模型(年龄校正致密面积)为0.61(P < .001);评分前8%时,AISmartDensity识别152/455(33%)未来癌症,PPV为2.91%,最佳密度模型识别57/455(13%),PPV为1.09%(P < .001);AISmartDensity识别间期癌41/130(32%)和下一轮筛查检出癌111/325(34%),最佳密度模型分别识别21/130(16%)和30/325(9%)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Mammographic density measurements are used to identify patients who should undergo supplemental imaging for breast cancer detection, but artificial intelligence (AI) image analysis may be more effective. Purpose To assess whether AISmartDensity-an AI-based score integrating cancer signs, masking, and risk-surpasses measurements of mammographic density in identifying patients for supplemental breast imaging after a negative screening mammogram. Materials and Methods This retrospective study included randomly selected individuals who underwent screening mammography at Karolinska University Hospital between January 2008 and December 2015. The models in AISmartDensity were trained and validated using nonoverlapping data. The ability of AISmartDensity to identify future cancer in patients with a negative screening mammogram was evaluated and compared with that of mammographic density models. Sensitivity and positive predictive value (PPV) were calculated for the top 8% of scores, mimicking the proportion of patients in the Breast Imaging Reporting and Data System "extremely dense" category. Model performance was evaluated using area under the receiver operating characteristic curve (AUC) and was compared using the DeLong test. Results The study population included 65 325 examinations (median patient age, 53 years [IQR, 47-62 years])-64 870 examinations in healthy patients and 455 examinations in patients with breast cancer diagnosed within 3 years of a negative screening mammogram. The AUC for detecting subsequent cancers was 0.72 and 0.61 (P < .001) for AISmartDensity and the best-performing density model (age-adjusted dense area), respectively. For examinations with scores in the top 8%, AISmartDensity identified 152 of 455 (33%) future cancers with a PPV of 2.91%, whereas the best-performing density model (age-adjusted dense area) identified 57 of 455 (13%) future cancers with a PPV of 1.09% (P < .001). AISmartDensity identified 32% (41 of 130) and 34% (111 of 325) of interval and next-round screen-detected cancers, whereas the best-performing density model (dense area) identified 16% (21 of 130) and 9% (30 of 325), respectively. Conclusion AISmartDensity, integrating cancer signs, masking, and risk, outperformed traditional density models in identifying patients for supplemental imaging after a negative screening mammogram. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Kim and Chang in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Liu Y, Sorkhei M, Dembrower K, et al. Use of an AI Score Combining Cancer Signs, Masking, and Risk to Select Patients for Supplemental Breast Cancer Screening. Radiology. 2024. PMID: 38591971. doi:10.1148/radiol.232535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。